A Multiple Dose Study Evaluating the Pharmacokinetics of an Oral Tablet Formulation of BNC210 in Healthy Volunteers
Bionomics Limited
20 participants
Jan 18, 2021
Interventional
Conditions
Summary
Bionomics Limited is developing BNC210 for the treatment of anxiety, and trauma- and stressor-related, disorders including Post-Traumatic Stress Disorder (PTSD). This single-centre study conducted in healthy volunteers, will evaluate the pharmacokinetics as well as the safety and tolerability, of multiple doses of an oral tablet formulation of BNC210, given over a 7-day period,
Eligibility
Inclusion Criteria8
- Agree to and be capable of signing informed consent form.
- Adult males or females aged 18-65 years (inclusive) at the time of providing informed consent.
- Body mass index within the range of 18-30 kg/m2 at screening
- Good general health without clinically significant renal, hepatic, cardiac or respiratory disease, as determined by the Investigator.
- Have suitable venous access for blood sampling.
- Ability to swallow tablets
- Females participants of childbearing potential who are not currently pregnant of breast feeding. Females not of childbearing potential must be postmenopausal (defined as cessation of regular menstrual periods for at least 12 months prior to Screening and confirmed by follicle stimulating hormone (FSH) levels in menopausal range at Screening).
- Agree to abstain from sexual intercourse or use a highly effective method of birth control if participant or partner of participant is of childbearing potential, for the duration of the study and for 3 months after the last dose of study drug. Highly effective methods of birth control include vasectomy, the use of a condom in combination with barrier methods, hormonal birth control (except oral contraception – see exclusion criterion 12) or intrauterine device. Requirement for contraception can be waived in certain circumstances (i.e. same sex relationships) if approved by the Sponsor.
Exclusion Criteria18
- Any medical condition that in the opinion of the Investigator may adversely impact on the participant’s ability to complete the study.
- Renal impairment as evidenced by estimated creatinine clearance, measured by the Cockcroft-Gault method of less than 90 mL/min.
- Have a laboratory value at the Screening Visit that is outside the normal range, unless it is judged by the Investigator as not clinically significant after appropriate evaluation.
- Plasma AST (aspartate transaminase), ALT (alanine transaminase), and ALP (alkaline phosphatase) tests in excess of 1.5 times the upper limit of normal at screening or Day -1.
- History of severe allergic or anaphylactic drug-related reactions.
- Known past or present mental health disorder.
- Concurrent use of any prescription medication, over the counter medication or complementary / alternative medication within 2 weeks prior to first dose.
- Consumption of grapefruit, grapefruit juice, red wine or St. John’s Wort within 2 weeks prior to first dose.
- Participation in another clinical trial of an investigational agent within 30 days of study entry.
- Known history of past or present infection with hepatitis C virus (HCV), hepatitis B (HBV) or human immunodeficiency virus (HIV) or a positive test for HCV, HBV or HIV at screening.
- Females who are pregnant, nursing, or intend to become pregnant during the study or within 3 months of their last dose of BNC210, or any males who plan to father/conceive a child within 3 months of their last dose of BNC210.
- Females who are currently taking oral hormonal contraception (except progestogen only contraception (e.g., “minipill”), including levonorgestrel-releasing intrauterine devices)
- Clinically significant abnormal ECG (12-lead) at the Screening Visit as determined by the Investigator.
- Participants who have a marked prolongation of the QTcF corrected interval (i.e., repeated demonstration of a QTcF interval >450 msec for males and >470 msec for females at Screening.
- Significant history of illicit drug or alcohol use or abuse (as determined by the Investigator) within 1 year of the Screening Visit.
- Unwillingness or inability to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the participant returning for visits on schedule.
- Blood donation (1 unit or more) within 1 month prior to the Screening Visit.
- Smoked cigarettes/e-cigarettes, tobacco and/or tetrahydrocannabinol containing products within 2 weeks prior to first dose.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
In Dose Period 1, each participant will receive a total of 12 doses of an oral tablet formulation of BNC210 over a 7 day period as follows: - single dose of 900 mg BNC210 on Day 1 - twice daily doses of 900 mg BNC210 on Days 2-6 - single 900 mg dose of BNC210 on Day 7 Based on the analysis of pharmacokinetic and safety data from Dose Period 1, a second dose level may be assessed (Dose Period 2) using either a 1,125 mg OR a 1,350 mg dose of BNC210. Dose Period 2 will follow the same dosing schedule as described for Dose Period 1. A separate group of 10 participants will be enrolled into each Dose Period
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12621000125820